134 related articles for article (PubMed ID: 1803618)
1. Standardization of factor IX: standards for "purified" factor IX concentrates.
Lamb MA; Fricke WA; Rastogi SC
Thromb Haemost; 1991 Nov; 66(5):548-51. PubMed ID: 1803618
[TBL] [Abstract][Full Text] [Related]
2. Study of a proposed international standard for blood coagulation factor IX.
Brozović M; Kirkwood TB; Robertson I
Thromb Haemost; 1976 Feb; 35(1):222-36. PubMed ID: 989189
[TBL] [Abstract][Full Text] [Related]
3. Validation of a procedure for potency assessing of a high purity factor VIII concentrate--comparison of different factor VIII coagulant assays and effect of prediluent.
Mazurier C; Parquet-Gernez A; Goudemand M
Thromb Haemost; 1990 Oct; 64(2):251-5. PubMed ID: 2125374
[TBL] [Abstract][Full Text] [Related]
4. Biological standardization of human interferon beta: establishment of a replacement world health organization international biological standard for human glycosylated interferon beta.
Meager A; Das RG
J Immunol Methods; 2005 Nov; 306(1-2):1-15. PubMed ID: 16226271
[TBL] [Abstract][Full Text] [Related]
5. Standardization of Factor VIII-IV. Establishment of the 3rd International Standard for Factor VIII: C concentrate.
Barrowcliffe TW; Curtis AD; Thomas DP
Thromb Haemost; 1983 Oct; 50(3):697-702. PubMed ID: 6417819
[TBL] [Abstract][Full Text] [Related]
6. Collaborative study for the establishment of replacement batches for human coagulation factor IX concentrate reference standards.
Gray E; Pickering W; Hockley J; Rigsby P; Weinstein M; Terao E; Buchheit KH
Pharmeuropa Bio; 2008 Dec; 2008(1):19-30. PubMed ID: 19220978
[TBL] [Abstract][Full Text] [Related]
7. Collaborative study on assays of activated FIX (FIXa). On behalf of the factor VIII and factor IX subcommittee of the ISTH. International Society on Thrombosis and Haemostasis.
Gray E; Walker D; Heath A; Barrowcliffe TW
Thromb Haemost; 1996 Dec; 76(6):1114-7. PubMed ID: 8972040
[TBL] [Abstract][Full Text] [Related]
8. Calibration of the WHO 5th IS for Blood Coagulation Factor IX, Concentrate and Ph. Eur. Human Coagulation Factor IX Concentrate Biological Reference Preparation Batch 3 and investigation of the suitability of an IS as potency standard for purified full-length recombinant FIX.
Gray E; Hogwood J; Dougall T; Rigsby P; Matejtschuk P; Terao E
Pharmeur Bio Sci Notes; 2021; 2021():26-68. PubMed ID: 33783349
[TBL] [Abstract][Full Text] [Related]
9. Calibration of human coagulation factor VII concentrate Ph. Eur. BRP batch 2.
Dodt J; Costanzo A; Daas A; Hunfeld A; Buchheit KH
Pharmeur Bio Sci Notes; 2010 Apr; 2010(1):31-8. PubMed ID: 20223188
[TBL] [Abstract][Full Text] [Related]
10. Comparison of six commercial plasma references for factor VIII, factor IX and von Willebrand factor. On behalf of the Subcommittee for Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
Kasper CK; Aronson DL; Davignon G; Foster P; Hillman-Wiseman C; Lusher JM; Manco-Johnson M; Meade JB; Montgomery RR; Rickles FR
Thromb Haemost; 1995 Sep; 74(3):987-9. PubMed ID: 8571334
[TBL] [Abstract][Full Text] [Related]
11. Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group.
White GC; Shapiro AD; Kurczynski EM; Kim HC; Bergman GE
Thromb Haemost; 1995 May; 73(5):779-84. PubMed ID: 7482403
[TBL] [Abstract][Full Text] [Related]
12. Performances of an artificial reagent for the one-stage factor IX assay.
Meunier L; Allain JP; Frommel D
Thromb Diath Haemorrh; 1975 Jun; 33(3):547-52. PubMed ID: 1154311
[TBL] [Abstract][Full Text] [Related]
13. Coagulation and chromogenic assays of factor VIII activity: general aspects, standardization, and recommendations.
Barrowcliffe TW; Raut S; Sands D; Hubbard AR
Semin Thromb Hemost; 2002 Jun; 28(3):247-56. PubMed ID: 12098084
[TBL] [Abstract][Full Text] [Related]
14. A collaborative study to establish a Korean Standard for factor VIII:C concentrate.
Kang HN; Kim SN; Lee SH; Hong SH
Thromb Res; 2004; 113(3-4):261-7. PubMed ID: 15140591
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of APTT reagent sensitivity to factor IX and factor IX assay performance. Results from the College of American Pathologists Survey Program.
Brandt JT; Arkin CF; Bovill EG; Rock WA; Triplett DA
Arch Pathol Lab Med; 1990 Feb; 114(2):135-41. PubMed ID: 2405809
[TBL] [Abstract][Full Text] [Related]
16. [Effect of substrate and diluent for factor VIII activity in highly purified factor VIII concentrate and patient plasma infused factor VIII concentrate].
Takahashi I; Furuta M; Mizuno S; Takamatsu J; Kamiya T
Rinsho Byori; 1993 Jul; 41(7):825-30. PubMed ID: 8361054
[TBL] [Abstract][Full Text] [Related]
17. The abnormal factor IX of hemophilia B+ variants.
Bertina RM; Veltkamp JJ
Thromb Haemost; 1978 Oct; 40(2):335-49. PubMed ID: 734633
[TBL] [Abstract][Full Text] [Related]
18. Biochemical and in vivo properties of high purity factor IX concentrates.
Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
[TBL] [Abstract][Full Text] [Related]
19. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
[TBL] [Abstract][Full Text] [Related]
20. Absence of correlation between X chromosome inactivation pattern and plasma concentration of factor VIII and factor IX in carriers of haemophilia A and B.
Orstavik KH; Scheibel E; Ingerslev J; Schwartz M
Thromb Haemost; 2000 Mar; 83(3):433-7. PubMed ID: 10744150
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
